肺癌患者合并肺栓塞的危险因素分析
Analysis of Risk Factors for Pulmonary Embolism in Lung Cancer Patients
DOI: 10.12677/acm.2024.1482309, PDF,    科研立项经费支持
作者: 王 云:成都中医药大学医学与生命科学学院,四川 成都;陈耀华*:达州市中心医院呼吸与危重症医学科,四川 达州
关键词: 肺腺癌肺栓塞危险因素治疗进展Lung Adenocarcinoma Pulmonary Embolism Risk Factors Treatment Progress
摘要: 肺癌是目前临床最常见且危害最大的恶性肿瘤之一,静脉血栓栓塞症(venous thromboembolism, VTE)是其常见的并发症,VTE包括深静脉血栓形成(deep venous thrombosis, VTE)和肺栓塞(pulmonary embolism, PE),大量研究表明,肺血栓栓塞(Pulmonary thromboembolism, PE)是肺癌患者住院期间除癌症本身以外的第二大死亡原因,病死率增加2~8倍,同时严重影响患者的生存时间及治疗费用,肺腺癌是非小细胞肺癌(non-small cell lung cancer, NSCLC)中VTE发生率最高的病理分型。但由于症状和体征缺乏特异性,临床上仅约1/4的患者有典型的“三联征”表现,即同时出现呼吸困难、咯血和胸痛,故症状缺乏特异性,难以识别,临床中易造成误诊和漏诊,对病人的生命安全构成极大的威胁,是肺癌患者预后不良的标志之一,故而对于肺癌病人发生肺栓塞的准确预测至关重要。本综述主要侧重于阐述肺腺癌患者形成PE的危险因素分析及相关治疗进展。
Abstract: Lung cancer is currently one of the most common and harmful malignant tumors in clinical practice, and venous thromboembolism (VTE) is a common complication. VTE includes deep venous thrombosis (VTE) and pulmonary embolism (PE). Numerous studies have shown that pulmonary thromboembolism (PE) is the second leading cause of death in lung cancer patients during hospitalization, after the cancer itself, with a mortality rate that increases by 2~8 times. At the same time, it seriously affects the patient’s survival time and treatment costs. Adenocarcinoma of the lung is a pathological classification with the highest incidence of VTE in non-small cell lung cancer (NSCLC). However, due to the lack of specificity in symptoms and signs, only about 1/4 of patients in clinical practice have typical “triad” symptoms, which include difficulty breathing, hemoptysis, and chest pain. Therefore, the symptoms lack specificity and are difficult to identify, which can easily lead to misdiagnosis and missed diagnosis in clinical practice, posing a great threat to the patient’s life safety and being one of the indicators of poor prognosis in lung cancer patients. Therefore, accurate prediction of pulmonary embolism in lung cancer patients is crucial. This review mainly focuses on the analysis of risk factors for PE formation in patients with lung adenocarcinoma and related treatment progress.
文章引用:王云, 陈耀华. 肺癌患者合并肺栓塞的危险因素分析[J]. 临床医学进展, 2024, 14(8): 973-979. https://doi.org/10.12677/acm.2024.1482309

参考文献

[1] da Costa, W.L., Guffey, D., Oluyomi, A., Bandyo, R., Rosales, O., Wallace, C.D., et al. (2022) Patterns of Venous Thromboembolism Risk, Treatment, and Outcomes among Patients with Cancer from Uninsured and Vulnerable Populations. American Journal of Hematology, 97, 1044-1054. [Google Scholar] [CrossRef] [PubMed]
[2] 陈诗雨, 罗专波. 肿瘤相关静脉血栓栓塞症研究进展[J]. 临床荟萃, 2024, 39(4): 363-369.
[3] 林玲, 吕静. 基于Caprini风险评估的快速康复外科对胸腔镜肺癌切除术后患者围手术期高凝状态及静脉血栓栓塞症的预防作用[J]. 实用医院临床杂志, 2022, 19(5): 6-9.
[4] Ma, R., Bi, Y., Kou, J., Zhou, J. and Shi, J. (2017) Enhanced Procoagulant Activity of Platelets after Chemotherapy in Non-Small Cell Lung Cancer. Cancer Biology & Therapy, 18, 627-634. [Google Scholar] [CrossRef] [PubMed]
[5] Li, Y., Shen, L., Huang, W., Hu, X., Xie, D., Yang, J., et al. (2018) Prevalence and Risk Factors of Acute Pulmonary Embolism in Patients with Lung Cancer Surgery. Seminars in Thrombosis and Hemostasis, 44, 334-340. [Google Scholar] [CrossRef] [PubMed]
[6] Königsbrügge, O., Pabinger, I. and Ay, C. (2014) Risk Factors for Venous Thromboembolism in Cancer: Novel Findings from the Vienna Cancer and Thrombosis Study (CATS). Thrombosis Research, 133, S39-S43. [Google Scholar] [CrossRef] [PubMed]
[7] Martín-Martos, F., Trujillo-Santos, J., del Toro, J., Bura-Riviere, A., Lorenzo, A., Barillari, G., et al. (2017) Gender Differences in Patients with Venous Thromboembolism and Five Common Sites of Cancer. Thrombosis Research, 151, S16-S20. [Google Scholar] [CrossRef] [PubMed]
[8] Kuderer, N.M., Poniewierski, M.S., Culakova, E., Lyman, G.H., Khorana, A.A., et al. (2017) Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). The Oncologist, 23, 247-255. [Google Scholar] [CrossRef] [PubMed]
[9] 黄平, 刘汉芸, 李玉红. 肺癌合并肺栓塞危险因素的Meta分析[J]. 临床荟萃, 2021, 36(12): 1061-1066.
[10] 吴巧莉, 蔡晓平, 吴月瑛, 等. 影响肺癌患者合并肺栓塞的相关危险因素分析[J]. 中国现代医生, 2021, 59(32): 109-12.
[11] 崔凯, 葛威, 卢晨, 等. 肺癌患者发生肺栓塞的相关危险因素分析[J]. 临床肺科杂志, 2020, 25(1): 96-100.
[12] 王林, 黄瓅, 窦学军. 老年晚期肺癌并发急性非大面积肺栓塞的高危因素分析[J]. 安徽医药, 2023, 27(1): 100-103.
[13] Ma, L. and Wen, Z. (2017) Risk Factors and Prognosis of Pulmonary Embolism in Patients with Lung Cancer. Medicine, 96, e6638. [Google Scholar] [CrossRef] [PubMed]
[14] Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R., et al. (2008) Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 381S-453S. [Google Scholar] [CrossRef] [PubMed]
[15] Junjun, L., Pei, W., Ying, Y. and Kui, S. (2020) Prognosis and Risk Factors in Older Patients with Lung Cancer and Pulmonary Embolism: A Propensity Score Matching Analysis. Scientific Reports, 10, Article No. 1272. [Google Scholar] [CrossRef] [PubMed]
[16] 罗水妹, 黄颂平, 许白兰, 等. 肺癌并发肺栓塞的危险因素及预后分析[J]. 广州医药, 2021, 52(2): 40-45.
[17] 王英芝, 陈霄云, 侯冬娇. 老年患者发生肺栓塞的危险因素及其预防措施分析[J]. 中国医院统计, 2018, 25(6): 474-475, 478.
[18] Chen, N., Ren, M., Li, R., Deng, X., Li, Y., Yan, K., et al. (2015) Bevacizumab Promotes Venous Thromboembolism through the Induction of PAI-1 in a Mouse Xenograft Model of Human Lung Carcinoma. Molecular Cancer, 14, Article No. 140. [Google Scholar] [CrossRef] [PubMed]
[19] Dou, F., Zhang, Y., Yi, J., Zhu, M., Zhang, S., Zhang, D., et al. (2020) Association of ALK Rearrangement and Risk of Venous Thromboembolism in Patients with Non-Small Cell Lung Cancer: A Prospective Cohort Study. Thrombosis Research, 186, 36-41. [Google Scholar] [CrossRef] [PubMed]
[20] 徐恺, 郑秀秀, 金儿. 肺癌合并肺栓塞的研究进展[J]. 浙江医学, 2021, 43(13): 1470-1474.
[21] Sandri, A., Papagiannopoulos, K., Milton, R., et al. (2015) Major Morbidity after Video-Assisted Thoracic Surgery Lung Resections: A Comparison between the European Society of Thoracic Surgeons Definition and the Thoracic Morbidity and Mortality System. Journal of Thoracic Disease, 7, 1174-1180.
[22] 黑晓欢, 张葆勋, 翟梦芳, 等. 肺癌患者术后住院期间发生肺栓塞的危险因素[J]. 血管与腔内血管外科杂志, 2023, 9(3): 300-303, 314.
[23] Saadeh, F.A., Norris, L., O’Toole, S. and Gleeson, N. (2013) Venous Thromboembolism in Ovarian Cancer: Incidence, Risk Factors and Impact on Survival. European Journal of Obstetrics & Gynecology and Reproductive Biology, 170, 214-218. [Google Scholar] [CrossRef] [PubMed]
[24] Lysov, Z., Swystun, L.L., Kuruvilla, S., Arnold, A. and Liaw, P.C. (2015) Lung Cancer Chemotherapy Agents Increase Procoagulant Activity via Protein Disulfide Isomerase-Dependent Tissue Factor Decryption. Blood Coagulation & Fibrinolysis, 26, 36-45. [Google Scholar] [CrossRef] [PubMed]
[25] Moik, F., Chan, W.E., Wiedemann, S., Hoeller, C., Tuchmann, F., Aretin, M., et al. (2021) Incidence, Risk Factors, and Outcomes of Venous and Arterial Thromboembolism in Immune Checkpoint Inhibitor Therapy. Blood, 137, 1669-1678. [Google Scholar] [CrossRef] [PubMed]
[26] 王渝胜. sPESI联合纤维蛋白原/白蛋白比值对急性非高危肺栓塞患者的预后价值[D]: [硕士学位论文]. 济南: 山东大学, 2021.
[27] 何丽, 赵玲, 施磊, 等. 血浆D-二聚体及纤维蛋白原对肺栓塞危险分层的意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(1): 137-139.
[28] 黄凯丽, 舒泸莹, 周晓莲, 等. 前白蛋白、白蛋白与D-二聚体在急性肺栓塞病情严重程度及预后中的预测价值[J]. 广西医科大学学报, 2023, 40(7): 1206-1211.
[29] 李萍, 苑群, 闫莹, 等. 血清学指标联合检测在急性肺栓塞诊断中的预警价值[J]. 宁夏医学杂志, 2023, 45(1): 26-29.
[30] 施旖旎, 金小岩, 罗克勤. 急性肺血栓栓塞血清酶学及肌钙蛋白I的变化研究[J]. 中国当代医药, 2014, 21(1): 131-133.
[31] Zhang, Y., Yang, Y., Chen, W., Guo, L., Liang, L., Zhai, Z., et al. (2014) Prevalence and Associations of VTE in Patients with Newly Diagnosed Lung Cancer. Chest, 146, 650-658. [Google Scholar] [CrossRef] [PubMed]
[32] 闵翼, 许雄伟. 妇科肿瘤患者抗凝药物预防静脉血栓栓塞的现况特点及合理性分析[J]. 中国医药科学, 2019, 9(7): 57-60.
[33] Wang, Q., Ma, J., Jiang, Z. and Ming, L. (2018) Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis. International Angiology, 37, 4-11. [Google Scholar] [CrossRef] [PubMed]
[34] 王子琛, 赵杰, 贾晓民, 等. 血清肿瘤标志物联合D-二聚体对NSCLC患者VTE的诊断[J]. 医学研究杂志, 2020, 49(0): 162-166.
[35] 陈粟. 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果观察[J]. 中国实用医药, 2022, 17(21): 22-25.
[36] 潘运昌, 卢璐春, 林瑞娟, 等. 低分子量肝素钙与利伐沙班联合治疗肺癌合并急性肺栓塞患者的效果[J]. 中外医疗, 2024, 43(1): 12-16.
[37] 焦建华, 李霞. 低分子肝素钙联合利伐沙班治疗急性肺栓塞的效果及对凝血功能、血管内皮功能的影响[J]. 临床误诊误治, 2021, 34(6): 49-54.
[38] Zhang, M., Wu, S. and Hu, C. (2020) Do Lung Cancer Patients Require Routine Anticoagulation Treatment? A Meta-Analysis. Journal of International Medical Research, 48, 1-14. [Google Scholar] [CrossRef] [PubMed]
[39] Lyman, G.H., Bohlke, K., Khorana, A.A., Kuderer, N.M., Lee, A.Y., Arcelus, J.I., et al. (2015) Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. Journal of Clinical Oncology, 33, 654-656. [Google Scholar] [CrossRef] [PubMed]
[40] Murphy, C.G., Moran, D.E., Gerstenmaier, J.F., Bruce-Brand, R., O’Toole, G.C., O’Rourke, S.K., et al. (2016) Evaluation of the Incidence of Pulmonary Embolus in the Early Postoperative Period Following Cemented Hemiarthroplasty. HIP International, 26, 295-300. [Google Scholar] [CrossRef] [PubMed]